1. Introduction {#sec0005}
===============

Steroidogenic factor-1 (SF-1, *NR5A1*, Ad4BP) was originally identified as a master-regulator of steroidogenic enzymes in the early 1990s following the seminal work of Keith L. Parker and Ken-ichirou Morohashi ([@bib0175; @bib0105; @bib0150]). SF-1 has since been shown to control many aspects of adrenal and reproductive function, and many factors involved in the development of these structures have been shown to be regulated by SF-1 ([@bib0155; @bib0125; @bib0190]).

In addition to numerous *in vitro* studies, significant early progress in understanding the *in vivo* function of SF-1 was obtained following deletion of the gene encoding Sf-1 (*Nr5a1*) in the mouse ([@bib0135; @bib0180; @bib0200]). Homozygous null mice (−/−) have adrenal agenesis, complete testicular dysgenesis, persistent Müllerian structures in XY animals, partial hypogonadotropic hypogonadism, and other features such as hyposplenism, abnormalities of the ventro-medial hypothalamus and late-onset obesity ([@bib0140]). Haploinsufficient animals were originally thought to have minimal phenotypes compared to the severe features seen in *Nr5a1* null littermates. However, more subtle phenotypes have also been found to be present in haploinsufficient animals following more detailed investigation ([@bib0030; @bib0035]), and newer molecular and transgenic strategies continue to elucidate the role SF-1 plays as a critical mediator of endocrine development and function ([@bib0065; @bib0080]).

In parallel with these *in vitro* and *in vivo* studies, it has emerged that SF-1 is also an important factor in several human diseases. It is more than a decade since the first case of human SF-1 disruption was described. At that time it seemed likely that SF-1 changes in humans would be rare events associated with specific phenotypes. However, more recent studies are revealing that variations in SF-1 may play a much greater role in human disease than was originally thought. Here, we review the range of human phenotypes that are emerging in association with SF-1/*NR5A1* variants. It is also worth noting that -- to date -- no complete deletions of *NR5A1* have been described; thus, it is not completely established whether complete loss of SF-1 is compatible with embryonic or fetal survival in humans.

2. The "classic" phenotype: adrenal and gonadal failure {#sec0010}
=======================================================

Initial attempts to find *NR5A1* mutations in humans focussed on individuals with primary adrenal insufficiency and complete 46,XY gonadal dysgenesis, a phenotype resembling the *Nr5a1* knock-out mouse. This phenotype is very rare in humans, but *NR5A1* mutations were identified and reported in two 46,XY patients with female genitalia, Müllerian structures (uterus and upper vagina), complete gonadal dysgenesis and primary adrenal failure.

The first individual described with this phenotype was found to have a *de novo* heterozygous p.G35E change in the P-box of SF-1 ([Fig. 1](#fig0005){ref-type="fig"}A and B) ([@bib0005]). This patient presented with salt-losing adrenal failure in early infancy and was thought to have a high block in steroidogenesis affecting both adrenal and testicular function (e.g. CYP11A1, STAR). However, the identification of a streak-like gonad ([Fig. 1](#fig0005){ref-type="fig"}C) and Müllerian structures was consistent with testicular dysgenesis rather than a steroidogenic defect, so disruption of a common developmental regulator such as SF-1 was hypothesized.

The p.G35E change affects a region that is critical for SF-1 function. It had been known for some time that the P-box of nuclear receptors is important in dictating DNA binding specificity through its interaction with DNA response elements in the regulatory regions of target genes ([@bib0215]). SF-1 is thought to bind to estrogen receptor-like response elements as a monomer. The P-box motif forms the principle DNA-binding interface of SF-1 by interacting with the major groove of DNA ([Fig. 1](#fig0005){ref-type="fig"}D). *In vitro* studies showed variable effects of this p.G35E alteration on DNA-binding and gene transactivation but with a significant loss of function in most cases ([@bib0085]). Although no strong dominant negative effects were seen, the p.G35E change may have a mild competitive or dominant negative effect in certain assay systems, or through interaction with co-regulators ([@bib0085; @bib0210]). Therefore, the phenotype may be the result of reduced SF-1 transactivation on multiple targets throughout the genome and at different stages of development. It is also not known whether skewed allelic expression could have resulted in different effects of this *NR5A1* mutation in different organs or whether -- despite extensive analysis -- a convert regulatory or intronic change could have reduced transcription or translation of the wild-type allele. Nevertheless, this case established that disruption of SF-1 could be associated with severe gonadal defects and significant adrenal dysfunction in humans.

The importance of SF-1 in regulating human adrenal and gonad development and function was confirmed following the report of an infant with a similar phenotype (primary salt-losing adrenal failure, 46,XY DSD, Müllerian structures) who had inherited a homozygous p.R92Q alteration in SF-1 in a recessive fashion ([Fig. 1](#fig0005){ref-type="fig"}A) ([@bib0010]). This change lies within the A-box of SF-1 and interferes with monomeric DNA binding stability ([Fig. 1](#fig0005){ref-type="fig"}D). Again, the effects of this homozygous change are complex and variable, but in a range of promoter assays mean functional activity was in the order of 30--40% of wild-type ([@bib0085; @bib0010; @bib0120]). However, the question of altered allelic expression or other genomic events was not an issue as the mutation was present on both alleles. The limited data available showed normal adrenal function in heterozygous carriers of this change, suggesting that disruption of both alleles is needed for the phenotype to be seen.

3. SF-1 and adrenal insufficiency {#sec0015}
=================================

Given the importance of SF-1 in adrenal development, the next obvious question to address was whether SF-1 changes could be detected in girls (46,XX) who present with primary adrenal insufficiency or in patients with adrenal insufficiency where no specific cause had been found.

3.1. 46,XX primary adrenal failure {#sec0020}
----------------------------------

In 2000, Biason-Lauber and Schoenle described a *de novo* heterozygous *NR5A1* change in a girl who had presented at 14 months of age with primary adrenal insufficiency and seizures ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0025]). The nucleotide transversion found was predicted to result in a p.R255L mutation in the proximal part of the ligand-like binding domain of the protein. The mutant SF-1 protein was reported to be transcriptionally inactive, but without a dominant negative effect. Of note, ovaries were detected by MRI scan and inhibin A was low normal for age, suggesting that this change in SF-1 had not disrupted ovarian development and that early indicators of ovarian function were intact. Thus, it appeared that SF-1 could be a cause of primary adrenal insufficiency in 46,XX girls.

3.2. Adrenal insufficiency of unknown etiology {#sec0025}
----------------------------------------------

The association of SF-1/*NR5A1* mutations with adrenal dysfunction raised the question whether specific changes in SF-1 could be found in patients with primary adrenal failure but in whom gonadal function appeared normal or only minimally affected. As SF-1 might interact with different co-factors and other co-regulators in different developing tissues, it was hypothesized that phenotypes affecting predominantly the adrenal gland or predominantly the gonad might exist. To address this, mutational analysis of *NR5A1* was undertaken in a cohort or phenotypic males (46,XY) and females (46,XX) with primary adrenal failure of unknown etiology, as well as a small group of 46,XY individuals with primary adrenal insufficiency and varying degrees of testicular dysfunction ([@bib0115]). Although changes in the related nuclear receptor DAX-1/*NR0B1* were found in a substantial proportion of boys with primary adrenal hypoplasia, no additional SF-1/*NR5A1* mutations were found that could be responsible for a predominantly adrenal phenotype. It seems, therefore, that changes in SF-1 are a relatively rare cause of primary adrenal failure in humans and that any such alterations might be expected to be associated with significant underandrogenization if present in 46,XY individuals.

4. SF-1 and 46,XY DSD {#sec0030}
=====================

In contrast to the relatively small number of *NR5A1* changes reported in association with adrenal failure, heterozygous *NR5A1* changes are emerging as a relatively frequent finding in patients with 46,XY disorders of sex development (46,XY DSD) but *without* adrenal insufficiency ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0125; @bib0095]). The first report of a heterozygous frameshift mutation resulting in disruption of SF-1 appeared in 2004 in a 46,XY female from Brazil who had presented with hypertension in early adulthood and who was found to have ambiguous genitalia ([@bib0045]). No gonadal tissue could be identified at laparoscopy. Two further case reports of heterozygous changes that are predicted to produce nonsense or frameshift changes in *NR5A1* appeared soon after in patients from Japan and France, respectively ([@bib0075; @bib0145]). As adrenal function was normal in all these cases, it was proposed that genetic events leading to haploinsufficiency of *NR5A1* could disrupt testicular development and function, whilst adrenal function -- at least until early adulthood -- remained intact. Two of these cases had arisen spontaneously and were likely to be *de novo* events, whereas parental DNA was not available in the third case.

4.1. The typical 46,XY DSD phenotype {#sec0035}
------------------------------------

Since these initial reports, an increasing number of heterozygous changes in *NR5A1* have been identified in patients with 46,XY DSD phenotypes ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0120; @bib0170; @bib0050; @bib0090; @bib0130; @bib0205; @bib0165; @bib0240]). Many cases described to date display a similar phenotype of ambiguous genitalia (or "clitoral enlargement") at birth, a urogenital sinus, small inguinal testes and absent or rudimentary Müllerian structures. Many of these patients have intact or rudimentary Wolffian structures. Often there is biochemical evidence of partial gonadal dysgenesis and significantly impaired androgen synthesis as shown by low levels of testosterone, inhibin B and AMH, and an elevation of FSH. In some cases, testosterone levels may be relatively normal at birth, thereby resulting in a phenotype similar to partial androgen insensitivity syndrome. Gonadal histology in these cases is variable but often shows relatively preserved architecture of the testis in infancy, but reduced size of seminiferous tubules ([Fig. 3](#fig0015){ref-type="fig"}A and B) ([@bib0120]). Usually Leydig and Sertoli cells are seen and normal or reduced numbers of germ cells are present ([Fig. 3](#fig0015){ref-type="fig"}B). Although data are still limited, it is possible that the testis may be at risk of progressive dysgenetic changes, especially if it remains in an inguinal or abdominal position ([Fig. 3](#fig0015){ref-type="fig"}C).

SF-1/*NR5A1* changes associated with these forms of 46,XY DSD are usually frameshift or nonsense changes, or missense changes that affect DNA-binding and gene transcription ([Fig. 2](#fig0010){ref-type="fig"}). In several cohort studies, SF-1 changes have been reported in approximately 10--15% of individuals with this phenotype ([@bib0120; @bib0090]). Although many of the heterozygous changes are *de novo* (or even possibly mosaic) events, about one-third of these changes have been shown to be inherited from the mother in a sex-limited dominant manner ([@bib0100]). These women are at potential risk of primary ovarian insufficiency (see Section [5](#sec0060){ref-type="sec"}) but, if this does not happen -- or if they complete their families before the onset of early menopause -- they can pass heterozygous changes in *NR5A1* on to several affected 46,XY children. This mode of transmission can mimic X-linked inheritance ([@bib0050; @bib0120; @bib0240]). The features in different affected family members can be variable. In addition, one family has been reported with a homozygous missense mutation (p.D293N) in the LBD of SF-1 ([@bib0130]). This change showed partial loss-of-function (50%) in gene transcription assays and, as expected, was inherited in an autosomal recessive manner. Thus, inheritance patterns associated with *NR5A1* changes can be *de novo* (autosomal dominant), sex-limited dominant or autosomal recessive.

Further evidence for the effects of haploinsufficiency of *NR5A1* has been obtained from individuals with deletion of the locus containing *NR5A1* on one allele. In one 46,XY individual with clitoromegaly, a shallow vaginal entrance and one small palpable gonad, a 9q33 deletion including *NR5A1* was found by array comparative genomic hybridization (CGH) ([@bib0225]). Furthermore, a contiguous gene deletion syndrome involving 9q33.3--q34.11 has been reported in a patient with genitopatellar syndrome, ambiguous genitalia and bilateral ovotestes ([@bib0195]).

4.2. The severe 46,XY DSD phenotype {#sec0040}
-----------------------------------

At the more severe end of the spectrum, *NR5A1* mutations can be found in 46,XY girls who present in late puberty with primary amenorrhea ([Fig. 4](#fig0020){ref-type="fig"}). One woman with clitoromegaly and a normal vaginal opening was found to have very small fibrous gonads in the pelvis containing disorganized tubules and Leydig cell hyperplasia ([@bib0130]). The mutation found in this case (p.M1I) affects the start codon and is likely to disrupt translation initiation of the mRNA. Other patients reported have severe gonadal dysgenesis with female external genitalia, a normal vagina, a small uterus and streak gonads. In at least two of these cases, a disruptive heterozygous change in SF-1 is present together with the p.G146A polymorphism and it has been speculated that this combination may have contributed to the more severe phenotype ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0170; @bib0090]). More recently, SF-1 mutations have been described in 5/15 46,XY female adolescents presenting with primary amenorrhea and with low testosterone levels ([@bib0165]). Clitoromegaly was present in three cases. A uterus was found in the one case where information was available. The authors concluded that SF-1 mutations are a frequent cause of this clinical phenotype.

4.3. SF-1 and hypospadias {#sec0045}
-------------------------

At the less severe end of the spectrum, *NR5A1* mutations have also been detected in 46,XY patients with severe hypospadias and small inguinal testes due to partial gonadal dysgenesis and/or reduced androgen synthesis ([Figs. 2 and 3C](#fig0010 fig0015){ref-type="fig"}). The first case described with this phenotype harbors a heterozygous p.L437Q alteration in the ligand-like binding domain of SF-1 ([@bib0120]). This change is disruptive but may have partial function in some assay systems. Furthermore, three additional SF-1 alterations have been reported in a cohort of 60 boys with hypospadias ([@bib0095]). Of note, these three cases were found amongst the subset of individuals with the most severe forms of hypospadias (penoscrotal). All these cases had at least one undescended testis, and reduced penile length was found in two of the three cases.

4.4. SF-1 and bilateral anorchia {#sec0050}
--------------------------------

*NR5A1* was considered a candidate gene for bilateral anorchia based on the knowledge that a subset of these cases are familial, approximately half of all cases are associated with reduced penile length, and that some genes involved in testis development may be required to maintain testicular integrity in the postnatal period. In a study of a cohort of 24 boys with bilateral anorchia (vanishing testis syndrome) in France, one individual was found to carry a heterozygous SF-1 mutation (p.V355M) ([@bib0160]). One very small testis and one absent testis were found in early infancy with undetectable AMH. Testis atrophy and fibrosis was documented later in childhood. However, the patient\'s twin brother who harbored the same mutation is reported to have undergone normal puberty. This finding indicates that SF-1 may also play a role in maintaining the testis, but most likely the contribution of other unknown factors or altered expression of the mutant allele is responsible for the variability of phenotypes seen.

4.5. SF-1 and male factor infertility {#sec0055}
-------------------------------------

Recently, Bashamboo and co-workers investigated whether changes in SF-1 could be found in a cohort of 315 men with non-obstructive male factor infertility where the underlying cause was unknown ([@bib0020]). Men had been pre-screened for Y chromosome microdeletions and Klinefelter syndrome, and any cases where there was a potential known environmental or medical cause of infertility were excluded. Of note, there was no history of hypospadias or undescended testes. Analysis of *NR5A1* in this cohort identified changes in seven individuals. All these changes were located within the hinge region of the protein ([Fig. 2](#fig0010){ref-type="fig"}). Importantly, no rare allelic variants (other than the known p.G146A polymorphism) were found following direct sequencing of the entire *NR5A1* gene in more than 600 known fertile control men, and the changes found in association with infertility were not found to be present in more than 4000 control alleles. The men who harbored *NR5A1* changes had more severe forms of infertility (azoospermia, severe oligozoospermia) and in several cases low testosterone and elevated gonadotropins were found. In the one case studied, significant fibrosis of the testis with reduced seminiferous tubules and isolated rare germ cells was seen. A serial decrease in sperm count was found in one patient studied, raising the possibility that heterozygous changes in *NR5A1* might be transmitted to offspring in some cases, especially if fatherhood occurs in young adulthood rather than later in life. Indeed, the p.G123A + p.P129L variant has been found in several patients from Central, West and North Africa, suggesting that it may be a founder effect with low level penetrance through these populations. Taken together, this study shows that changes in SF-1 may be found in a small subset of phenotypically normal men with non-obstructive male factor infertility where the cause is currently unknown. These individuals may be at risk of low testosterone in adult life and may represent part of the adult testicular dysgenesis syndrome. Making the specific diagnosis in this group of patients could be important for long-term follow-up. Furthermore, an interaction between environmental or epigenetic factors and these specific SF-1 changes may be important in regulating the phenotype. Further studies will be needed to establish whether SF-1 changes can be found in other cohorts of infertile patients.

5. SF-1 and ovarian insufficiency {#sec0060}
=================================

*NR5A1* mutations have also now been identified in familial and sporadic forms of 46,XX primary ovarian insufficiency (POI) ([Fig. 2](#fig0010){ref-type="fig"}) ([@bib0130]). These 46,XX patients with *NR5A1* mutations presented with either primary or secondary amenorrhea, and with a variable age of onset of features. Primary gonadal failure was shown by elevated LH and FSH levels and low estradiol. In the one case studied, an ovarian biopsy showed extensive fibrosis with no evidence of follicles ([Fig. 3](#fig0015){ref-type="fig"}D). Most of these women harbored heterozygous alterations in *NR5A1* and had been identified on account of a history of 46,XY DSD and 46,XX POI in different individuals within the same family. In one large kindred a partial loss-of-function SF-1 change (p.D293N) was inherited in an autosomal recessive manner. Heterozygous SF-1/*NR5A1* changes were also found in two girls with sporadic forms of POI and no family history. Therefore, although some 46,XX women with *NR5A1* mutations have been described to have normal ovarian function and can transmit the mutation in a sex-limited dominant fashion, the detection of *NR5A1* alterations in 46,XX ovarian failure shows that SF-1 is also a key factor in ovarian development and function in humans. Disruption of SF-1 may affect the ovary at multiple levels, including reduced germ cell number, impaired stromal integrity, abnormal folliculogenesis and defective steroidogenesis. Some of these women may go through a stage of decreased ovarian reserve (with decreasing AMH and elevating gonadotropins) before manifesting clinical signs or symptoms of ovarian failure ([@bib0240]). Although more studies are needed to understand the natural history of these changes in more detail, and to establish how prevalent or predictable ovarian dysfunction might be, these cases do highlight that SF-1 plays a role in human ovarian function too.

6. The p.G146A polymorphism {#sec0065}
===========================

A p.G146A polymorphism (rs1110061; c.624G\>C) in SF-1 has been reported to be associated with micropenis or cryptorchidism in two relatively small studies of patients from Japan ([@bib0230; @bib0235]). This variant has potentially reduced function in some assay systems. Limited data have suggested that the presence of this p.G146A change together with haploinsufficiency of *NR5A1* may be associated with a more severe 46,XY DSD (see Section [4.2](#sec0040){ref-type="sec"}) ([@bib0090]). However, more studies are needed before the true significance of this potential effect is known.

7. Overactivity of SF-1 {#sec0070}
=======================

Whilst most studies have focused on loss of function of SF-1 and human disease, it is also becoming apparent that overexpression or overactivity of SF-1 might have an important clinical effect. SF-1 *overexpression* could result from (1) genomic duplications of the chromosomal locus containing *NR5A1* resulting in biologically significant copy number variation (CNV), or from (2) upregulation of *NR5A1* gene transcription due to increased promoter/enhancer activity or following decreased promoter methylation. Alternatively, *overactivity* of SF-1 could result from (1) increased protein stabilization or reduced degradation, (2) loss of SUMOylation-dependent repression of transcriptional activity, or (3) specific changes in the structure of SF-1 that result in increased basal activity or increased affinity for native and/or alternative ligands. Several of these mechanisms are now being seen as potential causes or modifiers of human disease, which has translational implications as pharmacomodulation of SF-1 might have a potential role in the treatment of these conditions ([@bib0190]).

7.1. Adrenal tumorigenesis {#sec0075}
--------------------------

Somatic duplications of 9q33 including *NR5A1* were originally described in 2005 in a cohort of children from Brazil with adrenocortical tumors (ACTs) ([@bib0070]). These changes occurred largely on the background of loss of heterozygosity for the tumor suppressor gene p53 (TP53). Increased *NR5A1* expression was subsequently confirmed in an independent study of ACTs, with a higher number of pediatric tumors showing *NR5A1* overexpression compared to adult tumors ([@bib0015]). Interestingly, increased nuclear SF-1 protein expression was seen in many cases, sometimes independently of detectable *NR5A1* gene expression. This finding as been supported by recent data from analysis of a large cohort of adult ACTs, which has shown a correlation between higher SF-1 protein levels and worse prognosis ([@bib0185]). Of note, SF-1 overexpression has been shown to increase proliferation and to decrease apoptosis of human adrenocortical cells, and to induce ACTs in transgenic mice ([@bib0055]). SF-1 inverse agonists have been shown to inhibit adrenocortical carcinoma cell proliferation *in vitro* ([@bib0060]).

7.2. Polycystic ovary syndrome {#sec0080}
------------------------------

A heterozygous point mutation (p.R365P) has been reported in a woman with polycystic ovary syndrome ([@bib0040]). The functional or clinical significance of this finding is unclear, but raises the possibility that conformational changes in the ligand-binding domain of SF-1 could have a biological effect.

7.3. Endometriosis {#sec0085}
------------------

SF-1 has been shown to be expressed in endometriotic cells whereas it is not usually detected in normal endometrium ([@bib0245]). Part of this aberrant expression may be the result of hypomethylation of a CpG-rich region in its proximal promoter region with subsequent activation by upstream stimulatory factor 2 (USF2) ([@bib0245; @bib0220]). Alternatively, SF-1 activity in endometriotic tissue may be increased following stimulation of the GPR30 estrogen receptor ([@bib0110]). Increased SF-1 expression or activity in endometriotic tissue could result in increased activity of StAR and aromatase, resulting in increased local estrogen synthesis, a key pathological feature of this condition ([@bib0220]).

8. Conclusions {#sec0090}
==============

SF-1 is clearly an important mediator of adrenal and reproductive function in humans. Changes in SF-1 activity have now been reported in association with a range of human conditions. Some of these conditions are rare, sporadic events due to "private" *de novo* changes in the coding sequence of *NR5A1* in an individual\'s genome. However, it is also emerging that specific changes in SF-1 may contribute to more common conditions such as male factor infertility or primary ovarian insufficiency. The exact pathogenic mechanisms in some of these cases are not entirely clear and phenotypes can be variable in some cases. Therefore, changes in SF-1 are likely to predispose an individual to a given phenotype but the ultimate clinical picture may be influenced by a number of oligogenic modulators, developmental switches, epigenetic influences, environmental stimuli and even imbalanced cis-regulation of mutant versus wild-type alleles when mutations are present in a heterozygous state. More systematic studies of SF-1 in different patient cohorts will be needed to address the natural history of some of these conditions and whether detecting a change in SF-1 might predispose to late-onset adrenal insufficiency, differences in tumor risk, or be important when exploring options for fertility preservation. Furthermore, the effects of SF-1 in tumorigenesis and in other physiological systems (e.g. appetite regulation, obesity, anxiety) might be important if data from mouse studies are extrapolated into humans ([@bib0190]). The next decade of human SF-1 research promises to be as exciting as the last.
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![Overview of SF-1 mutations associated with adrenal failure and 46,XY DSD. (A) Cartoon of SF-1 showing key functional domains and the position of the two SF-1 variants associated with this phenotype. (B) The amino-acid structure of the zinc fingers of the DNA-binding domain of SF-1 showing the proximal (P)-box motif and the glycine residue that is altered by the p.G35E mutation. (C) Streak-like gonads removed from the patient with the p.G35E change in late childhood (upper panel), containing poorly formed seminiferous tubules and connective tissue (lower panel). (D) Model of the DNA-binding domain of SF-1 bound to DNA based on the crystal structure of NGFI-B. The glycine at amino acid 35 (green) of the P-box forms the primary DNA-binding interface with the major groove of DNA and heterozygous disruption of this residue with replacement by glutamic acid is associated with a severe phenotype. In contrast, the arginine at amino acid 92 (yellow) affects the A-box of SF-1, which is important in stabilizing nuclear receptor binding. In this situation, homozygous disruption of the residue was associated with the severe adrenogonadal phenotype. Panels B and C reproduced with permission from [@bib0005] (copyright: Nature Publishing Group 1999). Panel D reproduced with permission from [@bib0010] (copyright: The Endocrine Society 2002).](gr1){#fig0005}

![Overview of reported changes in SF-1/*NR5A1* in humans. The approximate location of the change within the predicted structure of SF-1 is shown. Yellow shaded areas represent changes found in 46,XX girls or women. Grey and white areas represent changes in individuals with a 46,XY karyotype. Underlined changes were detected in a homozygous state. All other changes were present in a heterozygous state. An asterisk denotes cases where the p.G146A polymorphism was also detected. The missense mutation shown in italics is predicted to disrupt function, but data from functional assays have not been reported. In addition, deletion of *NR5A1* on one allele has been reported as part of a contiguous gene deletion syndrome. AI, adrenal insufficiency; DSD, disorder of sex development, POI, primary ovarian insufficiency. Modified with permission from [@bib0120] (copyright: The Endocrine Society 2002). For a complete overview of clinical and biochemical features associated with these changes, see [@bib0100].](gr2){#fig0010}

![Gonadal histology in 46,XY and 46,XX patients with *NR5A1* mutations. (A and B) Partial testicular dysgenesis in a patient with 46,XY DSD without adrenal failure. Testicular architecture was largely intact but seminiferous tubules were reduced in size. Sertoli, germ and Leydig cells were present. (original magnification 100× and 400× respectively; germ cells shown by arrows). (C) Testicular biopsy in a boy with severe penoscrotal hypospadias (original magnification 100×; seminiferous tubule hyalinization shown by arrowheads). (D) Ovarian dysgenesis in a patient with 46,XX primary ovarian insufficiency. Panels A--C reproduced with permission from [@bib0120] (copyright: The Endocrine Society 2007). Panel D reproduced with permission from [@bib0130] (copyright: © 2009 Massachusetts Medical Society).](gr3){#fig0015}

![The spectrum of phenotypes that have been reported in association with SF-1/*NR5A1* changes in humans (46,XY).](gr4){#fig0020}
